超敏C反应蛋白在COPD病程中的检测及其临床意义探讨

Exploration of the Detection and Clinical Significance of hs-CRP in COPD Patients

目的检测COPD患者急性发作期超敏C反应蛋白(hs-CRP)表达水平的变化,并探讨了其相关的临床意义。方法收集我院2010年6月至2011年6月收治的COPD急性发作期患者68例,COPD患者按肺功能损伤严重程度分为Ⅰ、Ⅱ、Ⅲ、Ⅳ四级。另取本院保健中心的健康体检者30例作为正常对照。胶乳增强免疫比浊法检测hs-CRP表达水平的变化。结果 COPD急性发作治疗前和治疗后hs-CRP分别为(16.42±5.43)和(9.61±2.33)μg/mL,均显著高于对照组的(5.58±1.24)μg/mL(P<0.01),hs-CRP在COPD急性发作治疗前也显著高于治疗后(P<0.01)。Ⅰ、Ⅱ、Ⅲ和Ⅳ级肺功能损伤COPD患者hs-CRP分别为(8.14±2.52)、(10.16±3.31)、(17.55±4.81)和(22.84±5.72)μg/mL,各组之间均具有显著性统计学差异(P<0.05)。结论 COPD急性发作期存在hs-CRP表达水平的升高,hs-CRP检测可以用于COPD患者急性加重期病情的监控。

Objective To investigate the changes of the level of serum hs-CRP in COPD patients with acute exacerba- tion and to explore its relevant clinical significance. Methods A total of 68 COPD cases with acute exacerbation were collected in our hospital from June 2010 to June 2011. All patients were divided into Class Ⅰ, Ⅱ , Ⅲ and Ⅳ according to the severity of pulmonary dysfunction. Another 30 healthy subjects from health-care centre were used as the normal control. The level of serum hs-CRP was measured with Latex enhanced immunoturbidimetric assay. Results The expression of serum hs-CRP was （ 16.42 ±5.43 and 9. 61±2. 33） μg/mL before and after treatment, which was significantly higher than that in control group （5.58±1.24） μg/mL （P 〈0. 01 ）. There was significant increase of hs-CRP before and after treatment （P 〈 0. 01 ）. The expression of hs-CRP in Ⅰ, Ⅱ , Ⅲ and Ⅳ pulmonary dysfunction classes was （8.14± 2. 52） , （10. 16 ± 3.31 ）, （17.55± 4. 81 ） and （22. 84± 5.72） μg/mL, respectively. There was significant statistical difference among different groups （ P 〈 0.05 ）. Conclusion The expression of hs-CRP increased in COPD patients with acute exacerbation, which could be used to monitor COPD oatients with acute exacerbation.